Archive | Abstracts

Combined population pharmacokinetic model of tenofovir and emtricitabine and their active intracellular metabolites in HIV Patients from the ANRS 134-COPHAR 3 trial

Tenofovir (TFV) and emtricitabine (FTC), which are part of the recommended highly active antiretroviral therapy for naïve HIV patients, show a large inter-individual pharmacokinetic (PK) variability so far unexplained. We model the concentrations of plasma TFV and FTC and their intracellular metabolites (TFV-DP and FTC-TP) collected after 4 and 24 weeks of treatment in 34 […]

Continue Reading

Covariate selection methods comparison, introducing the feature of a prior

Selecting the most externally predictive covariate of two correlated covariates can be difficult. In this study, we investigated 3 different covariate selection methods with respect to their predictive performance: a modified Stepwise Covariate Modelling (SCM), Full Fixed Effects Model (FFEM) and Prior-Adjusted Covariate Selection (PACS). The selection for SCM is agnostic (i.e. only data driven) […]

Continue Reading

Linearisation and automatic scale reduction of bone biology QSP models for data-driven analyses

Background: Bone biology is physiologically complex. Peterson et al [1] developed a QSP model consisting of 28 states that links integrated calcium homeostasis, hormonal control mechanisms and bone remodelling which consists of two continuous processes, (i) bone resorption coordinated by osteoclasts, and (ii) bone formation by osteoblasts. While the model naturally accommodates homeostatic mechanisms it […]

Continue Reading

Kinetic modelling of ligand mediated internalisation

Introduction: Internalisation is by its nature kinetic.  Hence, application of the standard assumption of equilibrium conditions used by pharmacologists to determine the equilibrium constant (KD) is not obvious for either the ligand-mediated internalisation pathway or other functional assays that occur over the same timeframe as internalisation.  However, it is also difficult or impossible to estimate […]

Continue Reading

Evaluation of assumptions underpinning pharmacometric models

Background: All models are underpinned by assumptions. The validity of any inference drawn from a model depends on the appropriateness and likely impact of the underlying assumptions [1]. However, in the literature surrounding quantitative pharmacology models and pharmacometrics, assumptions inherent to model development and use are not routinely acknowledged, described, or evaluated. This casts doubt […]

Continue Reading

A population pharmacokinetic model for 51Cr EDTA to estimate renal function

Background 51Cr EDTA is a radioisotope used to estimate glomerular filtration rate (GFR), particularly in patients receiving renally cleared anticancer agents such as carboplatin. We propose that current methods for determining 51Cr EDTA clearance from plasma radioactivity (counts/minute) result in biased estimates of GFR. The aims of the study were (i) to develop and test […]

Continue Reading

Pharmacokinetics and metabolism of dabrafenib and trametinib in BRAF V600E/K metastatic melanoma

Introduction. The combination of a BRAF inhibitor, dabrafenib and a MEK inhibitor, trametinib (CombiDT) has improved survival outcomes compared with chemotherapy or BRAF inhibitor monotherapy in advanced BRAF V600E/K melanoma. However, the use of CombiDT has a high incidence of pyrexia, causing treatment delays (Menzies, 2015). The pharmacokinetics and metabolism of dabrafenib and trametinib may […]

Continue Reading

ANZDATA: Pharmacology based time to event analysis for death and renal transplant failure

Background: The ANZDATA registry (http://www.anzdata.org.au/v1) has collected data on all patients receiving a renal transplant in Australia or New Zealand since 1977  Objective: To describe the effect of immunosuppressant medicines on time to death and time to renal transplant failure Methods: Demographic data and the daily dose of medicines used as immunosuppressants were extracted from […]

Continue Reading

Performance of a Theory-Based Mechanistic Model for Predicting the Target Dose of Warfarin

Background: Warfarin is widely used as a treatment of venous thromboembolism and its capability to reduce the hazard of thromboembolic events has been unequivocally demonstrated. Variability between individuals, as well as a narrow therapeutic range are barriers to safe and effective warfarin therapy. Inadequate dose individualization contributes to under-utilization, 18-55% of patients who would benefit […]

Continue Reading

Total and unbound mycophenolic acid pharmacokinetics before and after kidney transplantation

Background: An increased incidence of acute rejection is seen with underexposure to mycophenolic acid (MPA) in the initial week post kidney transplantation, particularly in high immunological risk patients (1,2). Up to 25% of individuals in contemporary drug regimens are below the proposed therapeutic range at this time (3), and these individuals cannot be identified a […]

Continue Reading